Potential role of lampalizumab for treatment of geographic atrophy

William Rhoades, Drew Dickson, Diana V. Do

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

The purpose of this article is to review the pathways underlying age-related macular degeneration and potential therapeutic targets, focusing on the complement pathway and the recent MAHALO Phase II trial of the investigational drug lampalizumab. This trial was the first to have shown positive results for the treatment of geographic atrophy in age-related macular degeneration. It has potential as a future treatment, and is currently undergoing a Phase III trial.

Original languageEnglish (US)
Pages (from-to)1049-1056
Number of pages8
JournalClinical Ophthalmology
Volume9
DOIs
StatePublished - Jun 11 2015

Fingerprint

Geographic Atrophy
Macular Degeneration
Investigational Drugs
lampalizumab
Therapeutics

Keywords

  • AMD
  • Age-related macular degeneration
  • Complement inhibition

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Potential role of lampalizumab for treatment of geographic atrophy. / Rhoades, William; Dickson, Drew; Do, Diana V.

In: Clinical Ophthalmology, Vol. 9, 11.06.2015, p. 1049-1056.

Research output: Contribution to journalReview article

Rhoades, William ; Dickson, Drew ; Do, Diana V. / Potential role of lampalizumab for treatment of geographic atrophy. In: Clinical Ophthalmology. 2015 ; Vol. 9. pp. 1049-1056.
@article{c599e537cabf4231b92ae5271945290b,
title = "Potential role of lampalizumab for treatment of geographic atrophy",
abstract = "The purpose of this article is to review the pathways underlying age-related macular degeneration and potential therapeutic targets, focusing on the complement pathway and the recent MAHALO Phase II trial of the investigational drug lampalizumab. This trial was the first to have shown positive results for the treatment of geographic atrophy in age-related macular degeneration. It has potential as a future treatment, and is currently undergoing a Phase III trial.",
keywords = "AMD, Age-related macular degeneration, Complement inhibition",
author = "William Rhoades and Drew Dickson and Do, {Diana V.}",
year = "2015",
month = "6",
day = "11",
doi = "10.2147/OPTH.S59725",
language = "English (US)",
volume = "9",
pages = "1049--1056",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Potential role of lampalizumab for treatment of geographic atrophy

AU - Rhoades, William

AU - Dickson, Drew

AU - Do, Diana V.

PY - 2015/6/11

Y1 - 2015/6/11

N2 - The purpose of this article is to review the pathways underlying age-related macular degeneration and potential therapeutic targets, focusing on the complement pathway and the recent MAHALO Phase II trial of the investigational drug lampalizumab. This trial was the first to have shown positive results for the treatment of geographic atrophy in age-related macular degeneration. It has potential as a future treatment, and is currently undergoing a Phase III trial.

AB - The purpose of this article is to review the pathways underlying age-related macular degeneration and potential therapeutic targets, focusing on the complement pathway and the recent MAHALO Phase II trial of the investigational drug lampalizumab. This trial was the first to have shown positive results for the treatment of geographic atrophy in age-related macular degeneration. It has potential as a future treatment, and is currently undergoing a Phase III trial.

KW - AMD

KW - Age-related macular degeneration

KW - Complement inhibition

UR - http://www.scopus.com/inward/record.url?scp=84934756694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934756694&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S59725

DO - 10.2147/OPTH.S59725

M3 - Review article

C2 - 26089637

AN - SCOPUS:84934756694

VL - 9

SP - 1049

EP - 1056

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -